{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:43:12Z","timestamp":1790768592868,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2020.113055","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T20:01:21Z","timestamp":1606766481000},"page":"113055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Non-hydroxamate inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): A critical review and future perspective"],"prefix":"10.1016","volume":"213","author":[{"given":"Sharyu","family":"Kesharwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-8842","authenticated-orcid":false,"given":"Sandeep","family":"Sundriyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.113055_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nchembio.2007.5","article-title":"The function of terpene natural products in the natural world","volume":"3","author":"Gershenzon","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.113055_bib2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1042\/bj2950517","article-title":"Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate","volume":"295","author":"Rohmer","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2020.113055_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1574-6968.1993.tb06375.x","article-title":"Isoprenoid biosynthesis in bacteria: two different pathways?","volume":"111","author":"Horbach","year":"1993","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.ejmech.2020.113055_bib4","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/acs.chemrev.6b00537","article-title":"The methylerythritol phosphate pathway to isoprenoids","volume":"117","author":"Frank","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev-biochem-052010-100934","article-title":"Methylerythritol phosphate pathway of isoprenoid biosynthesis","volume":"82","author":"Zhao","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2020.113055_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bioorg.2004.08.004","article-title":"1-Deoxy-D-xylulose 5-phosphate reductoisomerase: an overview","volume":"32","author":"Proteau","year":"2004","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib7","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1073\/pnas.95.17.9879","article-title":"A\u00a01-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-D-erythritol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis","volume":"95","author":"Takahashi","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.113055_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","article-title":"Antimicrobial resistance: a global multifaceted phenomenon","volume":"109","author":"Prestinaci","year":"2015","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.ejmech.2020.113055_bib9","first-page":"145","article-title":"The antimicrobial resistance crisis: causes, consequences, and management","volume":"2","author":"Michael","year":"2014","journal-title":"Front. Public Heal."},{"key":"10.1016\/j.ejmech.2020.113055_bib10","first-page":"277","article-title":"The antibiotic resistance crisis: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P\u00a0T J"},{"key":"10.1016\/j.ejmech.2020.113055_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1517\/17460441.2015.1048219","article-title":"Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?","volume":"10","author":"Penchovsky","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.113055_bib12","first-page":"832","article-title":"Current Technology in the discovery and development of novel antibacterials","volume":"18","author":"Chung","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2020.113055_bib13","first-page":"3","article-title":"Tackling threats and future problems of multidrug-resistant bacteria","author":"Medina","year":"2016","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2020.113055_bib14","doi-asserted-by":"crossref","first-page":"9740","DOI":"10.1021\/jm5010978","article-title":"Development of inhibitors of the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway enzymes as potential anti-infective agents","volume":"57","author":"Masini","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsinfecdis.7b00176","article-title":"The methylerythritol phosphate pathway: promising drug targets in the fight against tuberculosis","volume":"4","author":"Wang","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/138161207780618939","article-title":"Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme","volume":"13","author":"Singh","year":"2007","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.113055_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40588-014-0006-7","article-title":"Isoprenoid metabolism in apicomplexan parasites","volume":"1","author":"Imlay","year":"2014","journal-title":"Curr. Clin. Microbiol. Reports."},{"key":"10.1016\/j.ejmech.2020.113055_bib18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1099\/mic.0.051599-0","article-title":"Isoprenoid biosynthesis in bacterial pathogens","volume":"158","author":"Heuston","year":"2012","journal-title":"Microbiol."},{"key":"10.1016\/j.ejmech.2020.113055_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fcell.2020.00247","article-title":"Inhibitory effects of fosmidomycin against Babesia microti in\u00a0vitro","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2020.113055_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007806","article-title":"Potent, specific MEPicides for treatment of zoonotic staphylococci","volume":"16","author":"Edwards","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2020.113055_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/156802612799984599","article-title":"Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr): a review of the synthesis and biological evaluation of recent inhibitors","volume":"12","author":"Jackson","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2049-9957-3-28","article-title":"Tackling the existing burden of infectious diseases in the developing world: existing gaps and the way forward","volume":"3","author":"Bhutta","year":"2014","journal-title":"Infect. Dis. Poverty."},{"key":"10.1016\/j.ejmech.2020.113055_bib25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2174\/1381612043384006","article-title":"The MEP pathway: a new target for the development of herbicides, antibiotics and antimalarial drugs","volume":"10","author":"Rodr\u00edguez-Concepci\u00f3n","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.113055_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7164\/antibiotics.33.13","article-title":"Studies on new phosphonic acid antibiotics. I. FR-900098, isolation and characterization","volume":"33","author":"Okuhara","year":"1980","journal-title":"J.\u00a0Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2020.113055_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7164\/antibiotics.33.18","article-title":"Studies on new phosphonic acid antibiotics. II. Taxonomic studies on producing organisms of the phosphonic acid and related compounds","volume":"33","author":"Iguchi","year":"1980","journal-title":"J.\u00a0Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2020.113055_bib28","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1016\/S0040-4039(98)01755-9","article-title":"Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis","volume":"39","author":"Kuzuyama","year":"1998","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2020.113055_bib29","doi-asserted-by":"crossref","first-page":"19905","DOI":"10.1074\/jbc.M701935200","article-title":"Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysis","volume":"282","author":"Henriksson","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib30","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/jm5014264","article-title":"Synthesis and bioactivity of \u03b2-substituted fosmidomycin analogues targeting 1-Deoxy-D-xylulose-5-phosphate reductoisomerase","volume":"58","author":"Chofor","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/bi0118207","article-title":"E.\u00a0coli MEP synthase: Steady-state kinetic analysis and substrate binding","volume":"41","author":"Koppisch","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.113055_bib32","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1271\/bbb.67.2030","article-title":"Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli","volume":"67","author":"Sakamoto","year":"2003","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.ejmech.2020.113055_bib33","doi-asserted-by":"crossref","first-page":"8395","DOI":"10.1128\/JB.187.24.8395-8402.2005","article-title":"1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin","volume":"187","author":"Dhiman","year":"2005","journal-title":"J.\u00a0Bacteriol."},{"key":"10.1016\/j.ejmech.2020.113055_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20110039","article-title":"Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii","volume":"208","author":"Nair","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2020.113055_bib35","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1016\/j.bmcl.2011.09.123","article-title":"Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs","volume":"21","author":"Uh","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113055_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jmb.2004.10.030","article-title":"The crystal structure of E. coli 1-deoxy-D-xylulose-5-phosphate reductoisomerase in a ternary complex with the antimalarial compound fosmidomycin and NADPH reveals a tight-binding closed enzyme conformation","volume":"345","author":"Mac Sweeney","year":"2005","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.113055_bib37","doi-asserted-by":"crossref","first-page":"18401","DOI":"10.1074\/jbc.M300993200","article-title":"Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the catalytic mechanism and anti-malaria drug development","volume":"278","author":"Steinbacher","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib38","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/cbic.200500061","article-title":"A\u00a0fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase","volume":"6","author":"Merckl\u00e9","year":"2005","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.113055_bib39","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1021\/jo9024732","article-title":"Isoprenoid biosynthesis via the methylerythritol phosphate pathway: structural variations around phosphonate anchor and spacer of fosmidomycin, a potent inhibitor of deoxyxylulose phosphate reductoisomerase","volume":"75","author":"Zingl\u00e9","year":"2010","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bmcl.2013.11.067","article-title":"The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs","volume":"24","author":"Jackson","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113055_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/BJ20041378","article-title":"Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase","volume":"386","author":"Kuntz","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2020.113055_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejmech.2020.113055_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Franco","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsmedchemlett.5b00157","article-title":"Molecular property design: does everyone get it?","volume":"6","author":"Leeson","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113055_bib46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/cid\/cix1122","article-title":"Efficacy and safety of fosmidomycin\u2013piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: a single-arm, age de-escalation proof-of-concept study in Gabon","volume":"66","author":"Mombo-Ngoma","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib47","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1086\/381785","article-title":"Fosmidomycin-Clindamycin for Plasmodium falciparum infections in African children","volume":"189","author":"Borrmann","year":"2004","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib48","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.01448-06","article-title":"Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria","volume":"51","author":"Oyakhirome","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.113055_bib49","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1007\/s00436-002-0770-9","article-title":"Fosmidomycin for the treatment of malaria","volume":"90","author":"Wiesner","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejmech.2020.113055_bib50","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1021\/jm300652f","article-title":"\u03b1-Substituted \u03b2-oxa isosteres of fosmidomycin: synthesis and biological evaluation","volume":"55","author":"Br\u00fccher","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib51","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1016\/j.bmc.2007.12.001","article-title":"Synthesis of \u03b2- and \u03b3-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates","volume":"16","author":"Haemers","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejmech.2012.02.031","article-title":"Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents","volume":"51","author":"Ponaire","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-07159-y","article-title":"MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis","volume":"7","author":"Edwards","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.113055_bib54","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ardp.200700107","article-title":"\u03b3-substituted bis(pivaloyloxymethyl)ester analogues of fosmidomycin and FR900098","volume":"340","author":"Kurz","year":"2007","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2020.113055_bib55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/acsinfecdis.6b00125","article-title":"Structure-activity relationships of the MEPicides: N-acyl and O-linked analogs of FR900098 as inhibitors of dxr from Mycobacterium tuberculosis and Yersinia pestis","volume":"2","author":"San Jose","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib56","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cmdc.201600249","article-title":"Targeting an aromatic hotspot in Plasmodium falciparum 1-Deoxy-d-xylulose-5-phosphate reductoisomerase with \u03b2-arylpropyl analogues of fosmidomycin","volume":"11","author":"Sooriyaarachchi","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.113055_bib57","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1021\/jm4006498","article-title":"DXR inhibition by potent mono- and disubstituted fosmidomycin analogues","volume":"56","author":"Jansson","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib58","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.bmcl.2005.12.082","article-title":"Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors","volume":"16","author":"Haemers","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113055_bib59","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bmc.2016.11.040","article-title":"Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases","volume":"25","author":"Munier","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib60","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1021\/jm4012559","article-title":"IspC as target for antiinfective drug discovery: synthesis, enantiomeric separation, and structural biology of fosmidomycin thia isosters","volume":"56","author":"Kunfermann","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib61","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1021\/jm2000085","article-title":"Design, synthesis, and X-ray crystallographic studies of \u03b1-aryl substituted fosmidomycin analogues as inhibitors of mycobacterium tuberculosis 1-deoxy-d-xylulose 5-phosphate reductoisomerase","volume":"54","author":"Andaloussi","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","article-title":"UCSF ChimeraX: meeting modern challenges in visualization and analysis","volume":"27","author":"Goddard","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2020.113055_bib63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/ml100243r","article-title":"Structures of 1-deoxy-D-xylulose-5-phosphate reductoisomerase\/lipophilic phosphonate complexes","volume":"2","author":"Deng","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113055_bib64","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1021\/ja040126m","article-title":"Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5- phosphate reductoisomerase complexes","volume":"126","author":"Yajima","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113055_bib65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/oxfordjournals.jbchem.a003105","article-title":"Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase complexed with cofactors: implications of a flexible loop movement upon substrate binding","volume":"131","author":"Yajima","year":"2002","journal-title":"J.\u00a0Biochem."},{"key":"10.1016\/j.ejmech.2020.113055_bib66","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/ml300419r","article-title":"Antimalarial and structural studies of pyridine-containing inhibitors of 1-deoxyxylulose-5-phosphate reductoisomerase","volume":"4","author":"Xue","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113055_bib67","series-title":"Discovery Studio Visulaizer, 20.1.0","year":"2020"},{"key":"10.1016\/j.ejmech.2020.113055_bib68","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ccr.2007.08.001","article-title":"Traversing the coordination chemistry and chemical biology of hydroxamic acids","volume":"252","author":"Codd","year":"2008","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0020-1693(00)93409-1","article-title":"Transition metal complexes of monohydroxamic acids","volume":"35","author":"Brown","year":"1979","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2020.113055_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0020-1693(00)93417-0","article-title":"The infrared spectra of monohydroxamic acid complexes of copper, iron and nickel","volume":"35","author":"Brown","year":"1979","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2020.113055_bib71","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1021\/cr00097a011","article-title":"Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogues","volume":"89","author":"Miller","year":"1989","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not Be the best histone deacetylase inhibitors-what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.113055_bib73","first-page":"183","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2020.113055_bib74","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: a MedChem toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0003-9861(85)90838-0","article-title":"Metabolic activation of mutagenic N-hydroxyarylamines by O-acetyltransferase in Salmonella typhimurium TA98","volume":"239","author":"Saito","year":"1985","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2020.113055_bib76","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.113055_bib77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cardiores.2005.11.032","article-title":"The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors","volume":"69","author":"Peterson","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2020.113055_bib78","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1021\/jm00394a032","article-title":"In\u00a0vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase","volume":"30","author":"Summers","year":"1987","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib79","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1124\/dmd.104.000638","article-title":"Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice","volume":"32","author":"Sanderson","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2020.113055_bib80","doi-asserted-by":"crossref","DOI":"10.1021\/acs.accounts.7b00242","article-title":"A\u00a0bioinorganic approach to fragment-based drug discovery targeting metalloenzymes","volume":"50","author":"Cohen","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2020.113055_bib81","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1021\/acs.jmedchem.8b01868","article-title":"Metal-binding pharmacophore library yields the discovery of a glyoxalase 1 inhibitor","volume":"62","author":"Perez","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib82","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1021\/acs.inorgchem.8b01632","article-title":"Metal-binding isosteres as new scaffolds for metalloenzyme inhibitors","volume":"57","author":"Dick","year":"2018","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib83","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acs.chemrev.8b00201","article-title":"Targeting metalloenzymes for therapeutic intervention","volume":"119","author":"Chen","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib84","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2019.01.018","article-title":"Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: a perspective","volume":"165","author":"Jiang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib85","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1021\/jm9012592","article-title":"Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase","volume":"52","author":"Deng","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib86","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1021\/jm200363d","article-title":"Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies","volume":"54","author":"Deng","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib87","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1016\/j.bmcl.2011.07.005","article-title":"Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis","volume":"21","author":"Andaloussi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113055_bib88","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.bmc.2010.11.062","article-title":"Bioorganic & medicinal chemistry synthesis and evaluation of phosphonated N -heteroarylcarboxamides as DOXP-reductoisomerase (DXR) inhibitors","volume":"19","author":"Bodill","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib89","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1016\/j.bmc.2013.04.076","article-title":"Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors","volume":"21","author":"Bodill","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib90","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1016\/j.bmc.2016.04.021","article-title":"Synthesis and antimalarial activity of N-benzylated (N-arylcarbamoyl)alkylphosphonic acid derivatives","volume":"24","author":"Adeyemi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib91","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1016\/j.bmcl.2012.09.021","article-title":"Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR)","volume":"22","author":"Zingle","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113055_bib92","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1016\/j.bmcl.2011.07.005","article-title":"Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis","volume":"21","author":"Andaloussi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113055_bib93","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3390\/molecules19022571","article-title":"Synthetic fosmidomycin analogues with altered chelating moieties do not inhibit 1-deoxy-d-xylulose 5-phosphate reductoisomerase or Plasmodium falciparum growth in\u00a0vitro","volume":"19","author":"Chofor","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.113055_bib94","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1021\/acsomega.9b01774","article-title":"Synthesis and antimicrobial evaluation of \u03b3-borono phosphonate compounds in Escherichia coli and Mycobacterium smegmatis","volume":"4","author":"Mancini","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2020.113055_bib95","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/ja00905a001","article-title":"Hard and soft acids and bases","volume":"85","author":"Pearson","year":"1963","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113055_bib96","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1021\/ja9906960","article-title":"Manganese as a replacement for magnesium and zinc: functional comparison of the divalent ions","volume":"121","author":"Bock","year":"1999","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113055_bib97","doi-asserted-by":"crossref","first-page":"13945","DOI":"10.1021\/bi001497s","article-title":"Principles of hydroxamate inhibition of metalloproteases: carboxypeptidase A","volume":"39","author":"Mock","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.113055_bib98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/cr60106a002","article-title":"The hydroxamic acids","volume":"33","author":"Yale","year":"1943","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113055_bib99","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cmdc.200600204","article-title":"The design of inhibitors for medicinally relevant metalloproteins","volume":"2","author":"Jacobsen","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.113055_bib100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389557033488114","article-title":"Molecular diversity of hydroxamic acids: part I. Solution- and solid-phase synthesis","volume":"3","author":"Yang","year":"2003","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/138955706775197811","article-title":"Solid-Phase synthesis of biologically interesting compounds containing hydroxamic acid moiety","volume":"6","author":"Krchnak","year":"2005","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib102","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2174\/1385272823666190424142821","article-title":"Methods for hydroxamic acid synthesis","volume":"23","author":"Alam","year":"2019","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib103","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.drudis.2013.07.003","article-title":"Druggability of the enzymes of the non-mevalonate-pathway","volume":"18","author":"Masini","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.113055_bib104","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1172\/JCI129122","article-title":"Academia and industry: allocating credit for discovery and development of new therapies","volume":"129","author":"Flier","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2020.113055_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002866","article-title":"Finding new collaboration models for enabling neglected tropical disease drug discovery","volume":"8","author":"Pollastri","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062906","article-title":"The open access malaria box: a drug discovery catalyst for neglected diseases","volume":"8","author":"Spangenberg","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.113055_bib107","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40249-018-0444-1","article-title":"Innovation in neglected tropical disease drug discovery and development","volume":"7","author":"Weng","year":"2018","journal-title":"Infect. Dis. Poverty."},{"key":"10.1016\/j.ejmech.2020.113055_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001827","article-title":"Open source drug discovery in practice: a case study","volume":"6","author":"\u00c5rdal","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib109","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/ciw824","article-title":"The antibacterial resistance leadership group: progress report and work in progress","volume":"64","author":"Chambers","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.113055_bib110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1747-0285.2010.01060.x","article-title":"From Zn to Mn: the study of novel manganese-binding groups in the search for new drugs against tuberculosis","volume":"77","author":"Williams","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.113055_bib111","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci500588j","article-title":"DataWarrior: an open-source program for chemistry aware data visualization and analysis","volume":"55","author":"Sander","year":"2015","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.113055_bib112","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0968-0896(01)00429-1","article-title":"Insight into the stereochemistry in the inhibition of carboxypeptidase A with N-(hydroxyaminocarbonyl)phenylalanine: binding modes of an enantiomeric pair of the inhibitor to carboxypeptidase A","volume":"10","author":"Cho","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib113","doi-asserted-by":"crossref","first-page":"12569","DOI":"10.1021\/bi991043z","article-title":"Crystal structures of \u03b1-mercaptoacyldipeptides in the thermolysin active site: structural parameters for a Zn monodentation or bidentation in metalloendopeptidases","volume":"38","author":"Gaucher","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.113055_bib114","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1021\/acs.jmedchem.8b01363","article-title":"Structure-activity relationships in metal-binding pharmacophores for Influenza endonuclease","volume":"61","author":"Credille","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib115","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1021\/ja500616m","article-title":"\u201cUnconventional\u201d coordination chemistry by metal chelating fragments in a metalloprotein active site","volume":"136","author":"Martin","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113055_bib116","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1021\/jm500984b","article-title":"Exploring the influence of the protein environment on metal-binding pharmacophores","volume":"57","author":"Martin","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib117","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1747-0285.2010.01060.x","article-title":"From Zn to Mn: the study of novel manganese-binding groups in the search for new drugs against tuberculosis","volume":"77","author":"Williams","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.113055_bib118","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1039\/c3md00085k","article-title":"Design of potential bisubstrate inhibitors against Mycobacterium tuberculosis (Mtb) 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr)-evidence of a novel binding mode","volume":"4","author":"San Jose","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.ejmech.2020.113055_bib119","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1128\/AAC.00602-15","article-title":"Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr)","volume":"59","author":"Armstrong","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.113055_bib120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrd.2016.109","article-title":"Twenty years on: the impact of fragments on drug discovery","volume":"15","author":"Erlanson","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.113055_bib121","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1021\/ic0204272","article-title":"Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes","volume":"41","author":"Puerta","year":"2002","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib122","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.1021\/ja0485513","article-title":"New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups","volume":"126","author":"Puerta","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113055_bib123","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00775-018-1593-1","article-title":"Isosteres of hydroxypyridinethione as drug-like pharmacophores for metalloenzyme inhibition","volume":"23","author":"Adamek","year":"2018","journal-title":"J.\u00a0Biol. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib124","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1039\/c0dt01743d","article-title":"Emerging trends in metalloprotein inhibition","volume":"40","author":"Rouffet","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2020.113055_bib125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cmdc.200900516","article-title":"Chelator fragment libraries for targeting metalloproteinases","volume":"5","author":"Agrawal","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.113055_bib126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1747-0285.2011.01136.x","article-title":"Targeting metalloproteins by fragment-based lead discovery","volume":"78","author":"Johnson","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.113055_bib127","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fchem.2020.00093","article-title":"In silico strategies to support fragment-to-lead optimization in drug discovery","volume":"8","author":"de Souza Neto","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib128","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/17460441.2010.523697","article-title":"In silico fragment-based drug design","volume":"5","author":"Konteatis","year":"2010","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.113055_bib129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12248-018-0216-7","article-title":"Computational fragment-based drug design: current trends, strategies, and applications","volume":"20","author":"Bian","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2020.113055_bib130","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/ci900056c","article-title":"Comparison of several molecular docking programs: pose prediction and virtual screening accuracy","volume":"49","author":"Cross","year":"2009","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.113055_bib131","doi-asserted-by":"crossref","first-page":"8262","DOI":"10.1021\/ja00022a010","article-title":"Force field design for metalloproteins","volume":"113","author":"Hoops","year":"1991","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.113055_bib132","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1021\/jm060999m","article-title":"Prediction of protein-ligand interactions. Docking and scoring: successes and gaps","volume":"49","author":"Leach","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113055_bib133","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1023\/A:1021962616650","article-title":"Parametrization of a force field for metals complexed to biomacromolecuales: applications to Fe(II), Cu(II) and Pb(II)","volume":"16","author":"David","year":"2002","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2020.113055_bib134","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/jm040036s","article-title":"Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates","volume":"47","author":"Cheng","year":"2004","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:29:05Z","timestamp":1759328945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420310278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":132,"alternative-id":["S0223523420310278"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113055","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-hydroxamate inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): A critical review and future perspective","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113055"}}